touchCardio: Mikhail Kosiborod, ACC 2022: Results from the EMPULSE Trial

The EMPULSE trial showed the effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure.

touchCARDIO spoke with Dr. Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, MO) to discuss his presentation on the EMPULSE trial and the impact of SGLT-2 inhibitors and where they sit in the future treatment paradigm for heart failure.

Listen to the full touchCARDIO interview: Mikhail Kosiborod, ACC 2022: Results From the EMPULSE Trial: Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized For Acute Heart Failure

Related Content

Apr. 20, 2022

Congress Report: Results from the EMPULSE Trial
Dr. Mikhail Kosiborod talks about the additional analysis from the EMPULSE trial presented at the American College of Cardiology congress.
Medscape logo
Apr. 15, 2022

Medscape: Empagliflozin Rapidly Improves Acute Heart Failure Symptoms in Hospitalized Patients
EMPULSE trial shows treatment of patients acutely hospitalized for heart failure with empagliflozin led to a rapid incremental increase in patient well-being, compared with control patients who received placebo.
Apr. 14, 2022

HealthDay: Empagliflozin Offers Clinical Benefit in Heart Failure
A new study by Dr. Kosiborod and colleagues found clinical benefits in treatment with empagliflozin for patients hospitalized with acute heart failure.